Insmed Inc (INSM)vsKazia Therapeutics Ltd ADR (KZIA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
KZIA
Kazia Therapeutics Ltd ADR
$7.30
+2.38%
HEALTHCARE · Cap: $81.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 33056% more annual revenue ($606.42M vs $1.83M). KZIA leads profitability with a 0.0% profit margin vs -2.1%. KZIA appears more attractively valued with a PEG of 1.01. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
KZIA
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -38.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : KZIA
PEG of 1.01 suggests the stock is reasonably priced for its growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : KZIA
The primary concerns for KZIA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while KZIA is a value play — different risk/reward profiles.
KZIA carries more volatility with a beta of 1.63 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
KZIA generates stronger free cash flow (-9M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Kazia Therapeutics Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?